The Market Reports

Synopsis
The global market for Oral Proteins and Peptides was estimated to be worth US$ 2346 million in 2024 and is forecast to a readjusted size of US$ 6355 million by 2031 with a CAGR of 15.3% during the forecast period 2025-2031.
This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Oral Proteins and Peptides cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.
Polypeptide and protein drugs refer to the biological drugs of polypeptide and protein substances used for prevention, treatment and diagnosis. Polypeptide is a compound formed by linking α-amino acids together with a peptide chain, and it is also an intermediate product of proteolysis. N polypeptide chains are entangled in a certain spatial structure to form a protein. The hydrolysis of macromolecular proteins produces polypeptides. Such drugs are biochemical preparations and have relatively strict requirements on storage and transportation environment.
With the breakthrough of delivery technology, oral alternatives to injections have become a new trend, improving patient compliance and driving market growth.
The demand for oral protein and peptide drugs for the treatment of chronic diseases (such as diabetes and inflammatory bowel disease) continues to rise.
Nano-delivery systems and enzyme inhibition encapsulation technologies continue to mature, solving gastrointestinal degradation problems and expanding product development space.
Many biopharmaceutical companies around the world are advancing clinical trials and cooperative development to accelerate the commercialization process.
Despite regulatory challenges and cost pressures, the oral protein/peptide market is still seen as a high-potential blue ocean track.
This report aims to provide a comprehensive presentation of the global market for Oral Proteins and Peptides, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Oral Proteins and Peptides by region & country, by Type, and by Application.
The Oral Proteins and Peptides market size, estimations, and forecasts are provided in terms of sales volume (Kg) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oral Proteins and Peptides.
Market Segmentation
By Company
Ironwood & Allergan (AbbVie)
Novo Nordisk
Synergy Pharmaceuticals (Salix)
Novartis
Chiasma (Amryt Pharma)
Segment by Type
Linaclotide
Insulin
Plecanatide
Cyclosporine
Octreotide
Segment by Application
Gastric & Digestive Disorders
Bone Diseases
Diabetes
Hormonal Disorders
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Oral Proteins and Peptides manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Oral Proteins and Peptides in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Oral Proteins and Peptides in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Index